Novocuff, Inc.

Novocuff, Inc. is a medical device company based in Mountain View, California, dedicated to improving pregnancy outcomes and reducing preterm births globally. Founded in 2021 by Amy Degenkolb and Donald Lee, the company focuses on innovative technology to address major causes of preterm birth, particularly Preterm Premature Rupture of Membranes (PPROM) and cervical shortening. The flagship product, the Novocuff Cervical Control System (Novocuff CCS), is designed to stabilize and close the cervix, helping to retain amniotic fluid and sustain cervical length. This device aims to extend pregnancy duration and lower the risk of preterm birth, which is a significant cause of infant mortality worldwide. Novocuff is currently advancing the Novocuff CCS through pivotal clinical trials in the United States and is preparing for marketing submission to the U.S. Food and Drug Administration (FDA). The company has secured substantial funding to support its clinical development and regulatory approval, with backing from notable investors. Novocuff collaborates with healthcare providers, hospitals, and organizations focused on enhancing maternal and neonatal health.

• Employees 7